NRC-2694 is under clinical development by Natco Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect NRC-2694’s likelihood of approval (LoA) and phase transition for Recurrent Head And Neck Cancer Squamous Cell Carcinoma took place on 23 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NRC-2694 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
NRC-2694 is under development for the treatment of recurrent head and neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The drug is administered orally. It is a 6,7-dialkoxy quinazoline derivative, or salt derivative which possess anti-cancer activity. It acts by targeting the epidermal growth factor receptor (EGFR). It was also under development for advanced solid malignancies like non small cell lung cancer and HER-2 positive breast cancer.
Natco Pharma overview
Natco Pharma focuses on the discovery, development, manufacturing, and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosages in capsule, injection and tablet forms. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn’s disease, hypertension, myelodysplastic syndrome, prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) in the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.
Quick View NRC-2694 LOA Data
|Highest Development Stage|